BAQSIMI Basics

Keep the tube sealed until ready to use. Being exposed to moisture can cause BAQSIMI to not work as expected
Each BAQSIMI device contains 1 dose (3 mg) of glucagon nasal powder and can only be used once
BAQSIMI is for nasal use only
BAQSIMI should not be used past its expiration date
Remember to tell those close to you where you keep BAQSIMI

Carry BAQSIMI with you and keep BAQSIMI in the places you spend the most time – like home, work and school

Talk to your doctor about where the best place is for you to keep your BAQSIMI. Here are some places you may want to consider:

For Children

On/in a night stand

ICON GLUCOSE METER

Where other insulin or diabetes products are kept

At day care and/or with the babysitter

With the coach

At school

At the homes of family or close friends

For Adults

On/in a night stand

ICON GLUCOSE METER

Where other insulin or diabetes products are kept

At the workplace

With you when traveling

At the homes of family or close friends

At the gym or wherever you exercise

« How to use BAQSIMI?

Clinical use:
BAQSIMI has not been studied in pediatric patients less than 4 years old.

Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.

Contraindications:

Hypersensitivity to glucagon or to any ingredient in the formulation or container
Pheochromocytoma
Insulinoma

Most serious warnings and precautions:
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as possible.

States of starvation, adrenal insufficiency or chronic hypoglycemia: Because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.

Other relevant warnings and precautions:

Cardiovascular effects
Driving and operating machinery
Pheochromocytoma
Insulinoma
Sensitivity and resistance to glucagon
Pregnant women
Breast-feeding
Pediatrics (<4 years of age)
Geriatrics (>65 years of age)
Use in patients with Type 2 diabetes taking sulfonylureas
Use with alcohol
Monitoring and laboratory tests

For more information:
Consult the product monograph at http://pi.lilly.com/ca/baqsimi-ca-pm.pdf for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The product monograph is also available by calling 1-888-545-5972.